NASDAQ · AMGN
Amgen Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AMGN: Nov 03, 2026
Amgen Inc. Common Stock is expected to report earnings on 11/03/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 9 analysts' forecasts, the consensus EPS forecast for the quarter is $5.74. The reported EPS for the same quarter last year was $5.64.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $5.74 | $6.04 | $5.51 | 9 |
| Dec 2026 | $5.73 | $6.03 | $5.19 | 8 |
| Mar 2027 | $5.51 | $5.78 | $5.13 | 4 |
| Jun 2027 | $6.51 | $6.90 | $6.28 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · BNK Invest · The Motley Fool · Fintel- Zacks · Oct 29, 4:50 PM EDTAmgen (AMGN) Increases Despite Market Slip: Here's What You Need to KnowThe latest trading day saw Amgen (AMGN) settling at $460.73, representing a +1.97% change from its previous close.
- Zacks · Oct 29, 8:15 AM EDTAmgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline EstimatesBeyond analysts' top-and-bottom-line estimates for Amgen (AMGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
- BNK Invest · Oct 28, 12:01 PM EDTDaily Dividend Report: WFC,CTAS,WMB,ETN,BKR,AMGNWells Fargo announced its board of directors approved a quarterly common stock dividend of $0.50 per share, payable Dec. 1, 2026, to stockholders of record on Nov. 6, 2026. Cintas announced that the Company's Board of Directors approved a quarterly cash dividend of $0.52 per sh
- BNK Invest · Oct 28, 10:28 AM EDTDow Movers: SHW, HONIVIn early trading on Wednesday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the worst performing Dow component thus far
- Zacks · Oct 28, 10:20 AM EDTAmgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds?Amgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.
- Zacks · Oct 28, 9:00 AM EDTFoghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy?Foghorn Therapeutics (FHTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- The Motley Fool · Oct 27, 3:45 PM EDTAmgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug RevenueAmgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter.
- The Motley Fool · Oct 27, 11:10 AM EDTAmgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?Amgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025.
- Zacks · Oct 27, 9:00 AM EDTAmgen (AMGN) Reports Next Week: Wall Street Expects Earnings GrowthAmgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Fintel · Oct 27, 6:52 AM EDTAmgen Inc. Appoints David W. Gibbs to Board of Directors, Effective October 26, 2026On October 26, 2026, the Board of Directors of Amgen Inc. appointed David W. Gibbs as a director of the Company, effective immediately. Mr. Gibbs will serve as a member of the Board’s Audit Committee and its Compensation and Management Development Committee. Following the a
- Zacks · Oct 26, 8:50 AM EDTAre Medical Stocks Lagging Cronos Group (CRON) This Year?Here is how Cronos Group (CRON) and Amgen (AMGN) have performed compared to their sector so far this year.
- RTTNews · Oct 26, 6:09 AM EDTAmgen And AstraZeneca's IMDELLTRA Plus IMFINZI Cuts Death Risk By 58% In Small Cell Lung Cancer(RTTNews) – Amgen (AMGN) and AstraZeneca (AZN) reported Phase 3 results showing that IMDELLTRA combined with IMFINZI significantly improved survival in patients with extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer with historically poor outcome
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Amgen Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.